| Typicality: | 0.474 |
| Saliency: | 0.525 |
| in patients | 9 | other |
| in comparison to crizotinib | 8 | other |
| over an 8 week period | 5 | temporal |
| trial → be designed to evaluate → safety | 23 |
| trial → be designed to evaluate → the safety | 15 |
| trial → be designed to assess → safety | 13 |
| trial → be designed to measure → safety | 7 |
| trial → be designed to assess → the safety | 4 |
| trial → be designed to assess → both safety | 4 |
| trial → be designed to investigate → safety | 4 |
| trial → be designed to test → the safety | 3 |
| trial → be intended to evaluate → safety | 3 |
| trial → be to evaluate → safety | 3 |
| negative | neutral | positive |
| 0.046 | 0.827 | 0.127 |
| Raw frequency | 79 |
| Normalized frequency | 0.525 |
| Modifier score | 0.500 |
| Perplexity | 126.166 |